FGFR2 and neoplasm: As the presence of more small retrospective trials is unlikely to resolve the issue, we encourage the creation of accurate and well-designed prospective trials, with a good sample size including only iCCA, with a clear study population in mind (resected vs non resected, advanced vs early stage, FGFR2 translocations vs all FGFR mutations), and in which all confounding prognostic factors are described and taken into account at multivariate analysis, such as clinical characteristics, tumor histopathological features, coexisting mutations and treatment provided (Table 5).